Severe cognitive impairment

Orbis Announces Five-Year Partnership Renewal with OMEGA

Retrieved on: 
Monday, December 19, 2022
Qatar Executive, Ophthalmology, Woman, Golf, Qatar Airways, Nursing, Hamad International Airport, Better Business Bureau, OMEGA, Mentorship, Health, Swimming, Orbis International, Partnership, Naming, Hospital, Qatar Charity, Severe cognitive impairment, NASA, University, Cataract, Knowledge, Education, Olympic Games, Omega Speedmaster, Government, Organic, Qatar Fund for Development, MD-10, Development, Patient, Candid (organization), Management, Medicine, Orbis

NEW YORK, Dec. 19, 2022 /PRNewswire/ -- Today, eye care nonprofit Orbis International announced its renewed partnership with the Swiss watchmaker OMEGA, which will provide the organization with $2.5M over the next five years. The generous support will bolster Orbis's work to train eye care teams in areas with the greatest need so they can provide quality care to patients.

Key Points: 
  • OMEGA has been a proud supporter of Orbis since 2011, when it became a Global Corporate Partner.
  • Raynald Aeschlimann, President and CEO of OMEGA said, "It's an honour to extend our partnership with this life-changing organisation.
  • For more than a decade, OMEGA has been witnessing the incredible work of Orbis, who embrace our own values of innovation, pioneering spirit, and meaningful change.
  • OMEGA also works in cooperation with its brand ambassadors – including Daniel Craig, Cindy Crawford, and others – to increase awareness of Orbis and its mission.

LG PRESENTS ESG VISION FOR A BETTER LIFE FOR ALL AT CES 2023

Retrieved on: 
Monday, December 19, 2022
Electronics, Collection, Human, Voice recognition, CRC, Chilseo-myeon, EPS, Language, Reading, Commitment, Severe cognitive impairment, News, Home entertainment, GOOD, Wheelchair, LG Electronics, GHG, Changwon, Television, USD, LG, Better Life, Fusion Global Business Solutions, ESG, LG Corporation, CES, Renewable energy, Consumer electronics, Planet

SEOUL, South Korea, Dec. 19, 2022 /PRNewswire/ -- LG Electronics (LG) will be putting the spotlight on its continuing commitment to sustainability at CES 2023, showcasing its ESG vision and latest, impactful innovations in an exclusive exhibit dubbed the Better Life for All zone.

Key Points: 
  • SEOUL, South Korea, Dec. 19, 2022 /PRNewswire/ -- LG Electronics (LG) will be putting the spotlight on its continuing commitment to sustainability at CES 2023, showcasing its ESG vision and latest, impactful innovations in an exclusive exhibit dubbed the Better Life for All zone.
  • Key focuses of LG's ESG agenda have been built into every aspect of the Better Life for All zone.
  • Our Commitment, the third and final section of the Better Life for All zone, reflects LG's dedication to ensuring a sustainable future – the ultimate goal of the company's Better Life Plan 2030.
  • "At LG, we are constantly challenging ourselves to go the extra mile to make our vision for a Better Life for All a reality," said Lee Jeong-seok, head of LG Electronics' Global Marketing Center.

LG PRESENTS ESG VISION FOR A BETTER LIFE FOR ALL AT CES 2023

Retrieved on: 
Monday, December 19, 2022
Electronics, Collection, Human, Voice recognition, CRC, Chilseo-myeon, EPS, Language, Reading, Commitment, Severe cognitive impairment, News, Home entertainment, GOOD, Multimedia, Wheelchair, LG Electronics, GHG, Changwon, Television, USD, LG, Better Life, Fusion Global Business Solutions, ESG, LG Corporation, CES, Renewable energy, Online shopping, Consumer electronics, Planet

SEOUL, South Korea, Dec. 19, 2022 /PRNewswire/ -- LG Electronics (LG) will be putting the spotlight on its continuing commitment to sustainability at CES 2023, showcasing its ESG vision and latest, impactful innovations in an exclusive exhibit dubbed the Better Life for All zone.

Key Points: 
  • SEOUL, South Korea, Dec. 19, 2022 /PRNewswire/ -- LG Electronics (LG) will be putting the spotlight on its continuing commitment to sustainability at CES 2023, showcasing its ESG vision and latest, impactful innovations in an exclusive exhibit dubbed the Better Life for All zone.
  • Key focuses of LG's ESG agenda have been built into every aspect of the Better Life for All zone.
  • Our Commitment, the third and final section of the Better Life for All zone, reflects LG's dedication to ensuring a sustainable future – the ultimate goal of the company's Better Life Plan 2030.
  • "At LG, we are constantly challenging ourselves to go the extra mile to make our vision for a Better Life for All a reality," said Lee Jeong-seok, head of LG Electronics' Global Marketing Center.

Stonegate Healthcare Reviews Retinitis Pigmentosa

Retrieved on: 
Wednesday, December 14, 2022
IRD, Visual impairment, Severe cognitive impairment, Retinitis pigmentosa, Research, Patient, RP, Pharmaceutical industry, Telescopic sight

Dallas, Texas--(Newsfile Corp. - December 14, 2022) - Stonegate Healthcare has published a new report on Retinitis Pigmentosa (RP) and the pipeline of products in development.

Key Points: 
  • Dallas, Texas--(Newsfile Corp. - December 14, 2022) - Stonegate Healthcare has published a new report on Retinitis Pigmentosa (RP) and the pipeline of products in development.
  • Retinitis Pigmentosa (RP) is the leading cause of visual disability and blindness in patients under 60.
  • Stonegate Capital Partners is a leading advisory firm founded in 1972.
  • Our affiliate, Stonegate Capital Markets (Member FINRA/SIPC) provides a full spectrum of investment banking services and equity research.

Apellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic Atrophy

Retrieved on: 
Friday, December 16, 2022
European Medicines Agency, Creativity, Ophthalmology, Quality of life, Patient, United, Fast Track, AMD, Annual report, Security (finance), FDA, Marketing, Food, Safety, APLS, PDUFA, Science, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MAA, C3, Geographic atrophy, Retinal, GA, Severe cognitive impairment, Injection, University, Pharmaceutical industry, EU, OAKS
Key Points: 

    Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema

    Retrieved on: 
    Thursday, December 15, 2022
    Eye, CST, Patient, Inflammation, Disulfiram-like drug, PKI, MAD, Severe cognitive impairment, Safety, Diabetic retinopathy, Retina, Pharmacokinetics, DR, DME, World Diabetes Day, Diabetes, SAD, Visual acuity, Risk, Bradykinin, Kallikrein, Pathophysiology, HIV disease progression rates, Injection, Congenital hyperinsulinism, Pharmaceutical industry, Rezolution Pictures, Snellen

    The invasive route of administration, coupled with inadequate responsiveness in some patients, leads to overall undertreatment and suboptimal vision outcomes in DME patients.

    Key Points: 
    • The invasive route of administration, coupled with inadequate responsiveness in some patients, leads to overall undertreatment and suboptimal vision outcomes in DME patients.
    • Patients who have previously received more than three anti-VEGF injections prior to the study will be excluded.
    • The study is expected to enroll approximately 100 patients overall, across approximately 25 investigational sites in the United States.
    • Rezolute is also developing RZ402, an orally available plasma kallikrein inhibitor, for the treatment of diabetic macular edema.

    Zoho Launches Blended Conversations for Zoho Desk, Delivering Highly Contextual and Conversational Customer Service Experiences

    Retrieved on: 
    Thursday, December 15, 2022
    Constellation, Frustration, Friction, Epilepsy, Privacy, Dyslexia, Messenger, The Standard Edition of the Complete Psychological Works of Sigmund Freud, Research, Communication, Abiquo Enterprise Edition, Severe cognitive impairment, ITIL, Trust, UI, Astigmatism, CX, WeChat, Organization, Animation, Instant messaging, WhatsApp, Java Platform, Standard Edition, Online shopping, Zoho Corporation, Telegraphy

    In addition to Blended Conversations, Zoho also announced a technological overhaul of the user interface to make it simpler, faster, and more accessible to users with a wide spectrum of different needs -- the company's biggest steps towards improving digital accessibility to date. Updates include options to support: cognitive and dyslexia challenges; visual impairments including astigmatism; animation reduction for those with seizure disorders; customization capabilities for color-blindness.

    Key Points: 
    • New capabilities include Blended Conversations, a seamless combination of human-driven and bot-powered conversational service experiences, as well as several refinements to the user interface.
    • These developments enable customer service agents to improve engagement and deliver higher-value customer experiences, removing the guesswork for agents and drastically minimizing friction that often results in bad customer experiences.
    • Blended Conversations in Zoho Desk addresses exactly this outcome by cleverly combining human and bot agents while also reducing friction, frustration, and costs-to-serve."
    • Blended Conversations for Zoho Desk allows customer service agents to deliver the best experience in the moment by delegating the majority of manual and transactional tasks to bots, while remaining in control of the overall service experience.

    AI-Diagnostics Startup Altris AI Raises $1 Million To Prevent Blindness

    Retrieved on: 
    Wednesday, December 14, 2022
    DrChrono, EQT Partners, Ophthalmology, Vance DeGeneres, AMD, Optometry, OCT, Runa Capital, World Economic Forum, Pathology, Business, Motivation, University of Chicago Booth School of Business, Retina, F5 Networks, Black Rock, Education, Machine learning, Nevus, Ingram Micro, Severe cognitive impairment, General partnership, VCS, Disease, MariaDB, AI, University, Software as a service, Glaucoma, Medical device, Medical imaging, Acronis, Corel, Nginx, Huvitz

    Altris AI, which is a US-based startup originally from Ukraine, is building solutions for the $58 billion global ophthalmology market.

    Key Points: 
    • Altris AI, which is a US-based startup originally from Ukraine, is building solutions for the $58 billion global ophthalmology market.
    • Altris AI developed a SaaS platform based on 5 million OCT scans that detected and interpreted more than 100 pathologies and pathological signs.
    • Altris AI already partners with global OCT distributors and equipment manufacturers such as Topcon Healthcare, Optopol, and Huvitz.
    • Altris AI is developing an AI platform that assists eye care professionals in fighting blindness.

    Oxurion Announces the Continuation of KALAHARI Phase 2, Part B Study in Diabetic Macular Edema Following Interim Analysis

    Retrieved on: 
    Wednesday, December 14, 2022
    Eye, CST, KKS, Month, Euronext, Inflammation, Optical coherence tomography, Laser, Prevalence, Intravitreal injection, Caregiver burden, Sale, Safety, Severe cognitive impairment, Retina, IDMC, Part, DME, MD, Time-invariant system, Billie Eilish: The World's a Little Blurry, CFA, Diabetes, Plasma kallikrein, VEGF, Injection, Diabetic retinopathy, Steroid, Patient, Neurodegeneration, Pharmaceutical industry

    The IDMC recommended continuation of the study based upon the outcome of the futility analysis.

    Key Points: 
    • The IDMC recommended continuation of the study based upon the outcome of the futility analysis.
    • The IDMC assessment included an evaluation of interim efficacy and safety data from three-month data, with a total of 31 patients.
    • “We are very pleased to continue the KALAHARI trial following the IDMC’s recommendation after their review of our interim data,” said Andy De Deene, MD, Chief Development Officer of Oxurion.
    • Part B is the second part of the Phase 2 KALAHARI study, a two-part, randomized, prospective, multi-center study assessing multiple (3) injections of THR-149 in DME patients.

    Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA

    Retrieved on: 
    Monday, December 12, 2022
    Capital commitment, Euronext, SRS, Capital, Disclosure, Sale, Severe cognitive impairment, Cayman, Agreement, DME, EUR, USD, Plasma kallikrein, Diabetic retinopathy, Patient, Term Asset-Backed Securities Loan Facility, Pharmaceutical industry, Security (finance), Limited

    Negma Group has converted 380 convertible bonds in Oxurion resulting in a EUR 950,000 capital increase.

    Key Points: 
    • Negma Group has converted 380 convertible bonds in Oxurion resulting in a EUR 950,000 capital increase.
    • Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 411,071,559, outstanding ordinary shares carrying voting rights (compared to 311,281,644 outstanding ordinary shares previously).
    • This number will be used as the denominator for the calculation of the percentages of shareholdings.
    • Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties.